Hypera’s Stock Tumbles 14% Following Merger Proposal from EMS

On October 21, 2024, Hypera SA, a leading Brazilian pharmaceutical company, received a merger proposal from rival EMS. This potential merger could create Latin America’s largest pharmaceutical company, with annual net revenue approaching R$16 billion ($2.86 billion) and an EBITDA of about R$5 billion ($893 million). The news caused Hypera’s stock to plummet 14%, closing at R$21.95.

The proposed business combination requires approval from Hypera’s board and regulatory authorities. It would position the new entity as a leader across all pharmaceutical sectors, including prescription medications, generics, over-the-counter (OTC), and hospital medications. The combined company would hold about a 17% market share in Brazil.

EMS offered to acquire up to 20% of Hypera’s capital at R$30 per share, a 17% premium over the previous closing price. If fully accepted, EMS would invest R$3.8 billion ($678 million), funded internally.

Hypera’s Stock Tumbles 14% Following Merger Proposal from EMS

Despite similar revenues, Carlos Sanchez, EMS’s CEO, is expected to become the largest shareholder, holding approximately 60% of the combined company’s capital. This is due to EMS’s net cash position of around R$500 million ($90 million), contrasted with Hypera’s debts totaling R$8.2 billion ($1.46 billion).

Analysts have expressed mixed reactions to the merger proposal:

• XP Investimentos called it a “radical solution”
• BTG Pactual noted uncertainties due to lack of additional guidance
• Goldman Sachs highlighted concerns about future performance
• Itaú BBA downgraded Hypera from “buy” to “neutral,” reducing their price target from R$37 ($6.61) to R$29 ($5.18)
• Bradesco BBI revised their 2025 price target to R$35 ($6.25) while maintaining a neutral stance

Hypera’s stock had already declined by 37% year-to-date. The company announced a share buyback program of up to 4% of outstanding shares in response to the lower stock price. As of October 21, 2024, Hypera’s stock was trading at 10.4 times projected 2025 earnings, below its historical average.

The outcome of this merger proposal could significantly impact Hypera’s future in the pharmaceutical industry, and investors and analysts will closely monitor the company’s performance in the coming quarters.

More: Brazil news in English, every day from The Rio Times.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.